ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers

FHS
July 21, 2023
3:15 am

The ECOG-ACRIN Cancer Research Group has enrolled the first patient in a new treatment trial to evaluate the effectiveness of adding nilotinib to standard paclitaxel chemotherapy.

Canagliflozin enhances senescent cell clearance, improving aging-related conditions

Whether sodium-glucose co-transporter 2 (SGLT2) inhibitors induce senolysis.

June 3, 2024

Innovative 3D cell culturing method offers new insights into cancer cell mechanics

Developing chemotherapy drugs against breast cancer is costly, slow, and often inefficient, with more than 95% of screened drug candidates failing in patient trials.

June 14, 2024

Vertex non-opioid therapy reduced pain in mid-stage trials, study shows

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have

August 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.